Efficacy and safety of vagus nerve stimulation in the treatment of refractory epilepsy.
10.11817/j.issn.1672-7347.2021.200209
- Author:
Zhuanyi YANG
1
;
Dingyang LIU
2
;
Zhiquan YANG
3
;
Xiaoyu CHEN
2
;
Yuxiang CAI
2
;
Jian LIU
2
;
Junmei ZHANG
2
;
Sushan LI
2
Author Information
1. Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha 410008, China. neuroyzy@csu.edu.cn.
2. Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha 410008, China.
3. Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha 410008, China. y66406914@163.com.
- Publication Type:Journal Article
- Keywords:
McHugh seizure outcome classifications;
refractory epilepsy;
vagus nerve stimulation
- MeSH:
Drug Resistant Epilepsy/therapy*;
Humans;
Magnetic Resonance Imaging;
Retrospective Studies;
Seizures;
Treatment Outcome;
Vagus Nerve Stimulation
- From:
Journal of Central South University(Medical Sciences)
2021;46(10):1096-1101
- CountryChina
- Language:English
-
Abstract:
OBJECTIVES:Vagus nerve stimulation (VNS) is a neuromodulative therapeutic technique for patients with drug-resistant epilepsy who are not suitable for resection or who have experienced a failed resection. This study aims to explore the efficacy and safety of VNS in patients with refractory epilepsy, and to analyze the influential factors for the efficacy.
METHODS:A retrospective review of clinical data were conducted for 35 patients, who were treated for refractory epilepsy through VNS surgery in the Department of Neurosurgery, Xiangya Hospital, Central South University from April 2016 to August 2019. All patients were analyzed in terms of the clinical and follow-up data.
RESULTS:After a mean follow-up of 26 months (6-47 months), outcome was as follows: 7 patients were MuHugh class I, 13 patients were MuHugh class II, 8 patients were MuHugh class III, and 7 patients were MuHugh class IV-V. The total efficacy rate in the short duration group was significantly higher than that in the long duration group (77.8% vs 50.0%,
CONCLUSIONS:VNS is a safe and effective option in treating patients with refractory epilepsy, especially for those with short duration.
